Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Unknown field was ignored: [Corporate Author]
Page 1
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Dig Liver Dis. 2019 May;51(5):632-639. doi: 10.1016/j.dld.2019.02.004. Epub 2019 Feb 19.
Dig Liver Dis. 2019.
PMID: 30872085
Review.
The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines A …
The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today …
Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
Macaluso FS, Leone S, Previtali E, Ventimiglia M, Armuzzi A, Orlando A; AMICI (Italian Inflammatory Bowel Disease Patients' Association) and IG-IBD (Italian Group for the Study of Inflammatory Bowel Disease).
Macaluso FS, et al.
Dig Liver Dis. 2020 Nov;52(11):1304-1309. doi: 10.1016/j.dld.2020.07.028. Epub 2020 Aug 14.
Dig Liver Dis. 2020.
PMID: 32807691
BACKGROUND: The viewpoint on biosimilars among patients with inflammatory bowel diseases (IBD) is largely unknown. AIMS: We aimed at exploring the confidence and opinion on biosimilars among Italian patients with IBD. METHODS: An anonymous, 20-i …
BACKGROUND: The viewpoint on biosimilars among patients with inflammatory bowel diseases (IBD) is largely unknown. AIMS …
Item in Clipboard
Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.
Macaluso FS, Principi M, Facciotti F, Contaldo A, Todeschini A, Saibeni S, Bezzio C, Castiglione F, Nardone OM, Spagnuolo R, Fantini MC, Riguccio G, Conforti S, Caprioli F, Viganò C, Felice C, Fiorino G, Correale C, Bodini G, Milla M, Scardino G, Vernero M, Desideri F, Bossa F, Guerra M, Ventimiglia M, Casà A, Rizzo G, Orlando A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Macaluso FS, et al.
Inflamm Bowel Dis. 2023 Jun 30:izad118. doi: 10.1093/ibd/izad118. Online ahead of print.
Inflamm Bowel Dis. 2023.
PMID: 37390400
No abstract available.
Item in Clipboard
Cite
Cite